5 Best High Growth Healthcare Stocks to Buy

3. argenx SE (NASDAQ:ARGX)

Number of Hedge Fund Holders: 48

New York City-based argenx SE (NASDAQ:ARGX) is a global immunology company focused on translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines targeting severe autoimmune diseases.

On November 16, argenx SE (NASDAQ:ARGX) announced that the European Commission approved SC injectable VYVGART (efgartigimod alfa) as an add-on to standard therapy for the treatment of generalized myasthenia gravis in adult patients. VYVGART® is now approved for both intravenous and self-administered subcutaneous use in Europe.

As of Q3 2023, argenx SE (NASDAQ:ARGX) was ranked 3^rd on our list of 13 high growth healthcare stocks to buy. The stock was held by 48 hedge funds with the total shares held by hedge funds valued at $2.3 billion.

In its Q3 2023 “Baron Health Care Fund” investor letter, Baron Funds made the following comments about argenx SE (NASDAQ:ARGX):

“In July, argenx reported positive data from a study of Vyvgart Hytrulo in adults with CIDP. The study met its primary endpoint demonstrating a significantly lower risk of relapse with Vyvgart Hytrulo versus a placebo. This positive data adds to the commercial opportunity for Vyvgart, which is in the early stages of commercial launch for the treatment of myasthenia gravis (MG). We estimate CIDP represents an additional $3 billion revenue opportunity. We believe Vyvgart and the subcutaneous version Vyvgart Hytrulo have the potential to generate at least $7 billion in peak sales in MG, CIDP, primary immune thrombocytopenia, and pemphigus vulgaris. Plus, the company is studying Vyvgart in other autoimmune diseases and the ultimate peak sales potential for the franchise could be much higher. We continue to believe argenx is a unique growth company with strong management.”